KVUE

#414
Kenvue Inc.
17.2550 USD
-0.72%
Sector: Valores de Consumo Defensivo
Básica: USD
Divisa de beneficio: USD
Rango diario
17.1650
17.2585
Rango anual
14.0200
19.1750
Cambio diario
-0.72%
Variación mensual
-1.96%
Variación en los últimos 6 meses
+14.42%
Cambio anual
+14.42%
Cierres anteriores
17.3800
Abrir
17.2300
Bid
Ask
Mínimo
17.1650
High
17.2585
Volumen
1 515
Ver el calendario completo

Financials

Visión general Informes Estadísticas Dividendos
Trimestre Año
  • Market Capitalization 33.0732 B
  • Employee 22 K
  • Founded 2022
  • CEO N/A
  • Website www.kenvue.com
  • Headquarter Delaware, United States
  • FIGI BBG01C79X561
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
22.62
Relación precio/flujo de caja
2.19
Dividendos por acción
0.82
Rendimiento por dividendo, %
4.8

Kenvue Inc

Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey. Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index. CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO.

Noticias